B. Markman

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Violeta Serra, Maurizio Scaltriti, Ludmila Prudkin et al. · Oncogene · 2011 · 534 citations · Full text

Medicine, Cancer Biology, Pharmacology +17

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

B. Markman, Josep Tabernero, Ian E. Krop et al. · Annals of Oncology · 2012 · 148 citations

Medicine, Oncology, Pharmacology +15

Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R

Andrea Riccardo Filippi, Jair Bar, Christos Chouaid et al. · ESMO Open · 2024 · 50 citations · Full text

Medicine, Oncology, Radiation Oncology +14

A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors

Patricia LoRusso, B. Markman, Josep Tabernero et al. · Journal of Clinical Oncology · 2009 · 39 citations

Medicine, Oncology, Pharmacology +15

Abstract CT119: CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors

Leisha A. Emens, John D. Powderly, Lawrence Fong et al. · Cancer Research · 2017 · 34 citations

Medicine, Oncology, Pharmacology +16